Autonomic dysfunction in diabetic rats is dose-dependently exacerbated by L-NAME-induced hypertension.
Exacerbates autonomic dysfunction in diabetic-hypertensive rat models; hypothesis-generating with no clinical implications yet.
This study investigated the effects of varying doses of L-NAME on arterial pressure (AP), baroreflex control, and heart rate (HR)/AP variability in the STZ-diabetic rat. Fifty-two male Wistar rats were injected with 50 mg/kg IV STZ (diabetes, D, n = 24) or citrate (controls, C, n = 28) 30 days before recordings. After 16 days, they received 14 days of oral L-NAME, 10 (H10) or 30 (H30) mg/kg, or water. Catheters were implanted into the femoral artery and vein (PE-10) for measurements in conscious rats; recorded data were analyzed on a beat-to-beat basis. Mean AP was higher in CH30 versus C and in DH10 and DH30 versus D rats. Reflex tachycardia was blunted in CH30 and DH30 rats (b = -1.81, -1.41, -0.48 in C, CH10, and CH30, respectively, P < 0.05 and b = -1.45, -1.19, -0.28 in D, DH10, and DH30, respectively, P < 0.05). Although HR and AP variability were reduced in CH30 and DH30 rats versus C and D rats, the DH30 rat had more accentuated dysfunction. All doses of L-NAME produced similar AP responses in experimental versus control groups, independent of the disease state (diabetes). Thus, autonomic dysfunction is more related to the L-NAME dose used and to the association of diabetes and hypertension than to AP values.
No takes yet. Share an insight, caveat, or question.
Balbinott et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: